[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 42 of about 42
1. Halberg F, Prem K, Halberg F, Norman C, Cornélissen G: Cancer chronomics I. Origins of timed cancer treatment: early marker rhythm-guided individualized chronochemotherapy. J Exp Ther Oncol; 2006;6(1):55-61
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer chronomics I. Origins of timed cancer treatment: early marker rhythm-guided individualized chronochemotherapy.
  • A 21-year old patient who presented in 1973 with a rare and highly malignant ovarian endodermal sinus tumor with spillage into the peritoneal cavity is alive and well today after receiving chronochemotherapy.
  • During the first four courses of treatment, medications were given at different circadian stages.
  • Complete blood counts and marker variables such as mood, vigor, nausea, and temperature were monitored around the clock and analyzed by cosinor to seek times of highest tolerance.
  • Remaining treatment courses were administered at a time corresponding to the patient's best drug tolerance, rather than extrapolating the timing of optimal cyclophosphamide administration from also-implemented parallel laboratory studies on mice.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2001 Sep;82(3):578-80 [11520160.001]
  • [Cites] Cancer. 2003 Jan 1;97(1):155-69 [12491517.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3808-13 [14551299.001]
  • [Cites] J Exp Ther Oncol. 2003 Sep-Oct;3(5):223-60 [14641812.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2971-2; author reply 2972 [15254067.001]
  • [Cites] Science. 1972 Jul 7;177(4043):80-2 [5041782.001]
  • [Cites] Experientia. 1973 Aug 15;29(8):909-34 [4582086.001]
  • [Cites] Obstet Gynecol. 1975 Feb;45(2):186-9 [1118091.001]
  • [Cites] Chronobiologia. 1974 Jul-Sep;1(3):270-7 [4465079.001]
  • [Cites] Chronobiologia. 1977 Jan-Mar;4(1):1-17 [880849.001]
  • [Cites] Cancer Treat Rep. 1978 Sep;62(9):1337-49 [688277.001]
  • [Cites] Cancer Treat Rep. 1979 Aug;63(8):1428-30 [476717.001]
  • [Cites] Chronobiologia. 1979 Jul-Sep;6(3):231-57 [520099.001]
  • [Cites] Prog Clin Biol Res. 1987;227B:349-56 [3628347.001]
  • [Cites] Chronobiologia. 1992 Jan-Mar;19(1-2):17-42 [1352750.001]
  • [Cites] In Vivo. 1992 Jul-Aug;6(4):403-27 [1520842.001]
  • [Cites] Chronobiologia. 1993 Jul-Dec;20(3-4):139-44 [8131663.001]
  • [Cites] In Vivo. 1995 Jul-Aug;9(4):269-78 [8555425.001]
  • [Cites] In Vivo. 1995 Jul-Aug;9(4):341-6 [8555433.001]
  • [Cites] Biomed Pharmacother. 2005 Oct;59 Suppl 1:S152-7 [16275485.001]
  • [Cites] N Engl J Med. 2006 Aug 24;355(8):850; author reply 850-1 [16929004.001]
  • [Cites] Am J Med. 2007 May;120(5):e19-20; author reply e21-2 [17466636.001]
  • (PMID = 17228525.001).
  • [ISSN] 1359-4117
  • [Journal-full-title] Journal of experimental therapeutics & oncology
  • [ISO-abbreviation] J. Exp. Ther. Oncol.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / GM013981-44; United States / NIGMS NIH HHS / GM / K06 GM013981; United States / NIGMS NIH HHS / GM / GM-13981; United States / NIGMS NIH HHS / GM / K06 GM013981-44
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS75750; NLM/ PMC2581882
  •  go-up   go-down


2. Kehila M, Skhiri R, Boughizane S, Fekih M, Kebaili S, Rameh S, Agina M, Khairi H: [Yolk sac tumor revealed by an ascite of great abundance]. J Gynecol Obstet Biol Reprod (Paris); 2009 Oct;38(6):516-20
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Yolk sac tumor revealed by an ascite of great abundance].
  • [Transliterated title] Tumeur vitelline de l'ovaire révélée par une ascite de grande abondance.
  • We report the case of a 16-year-old girl explored for an ascite of great abundance responsible for a respiratory embarrassment.
  • Its symptomatology proved to be secondary to a vitelline tumour of the ovary.
  • She had a conservative treatment followed up by a chemotherapy which allowed a clinical and biological remission.
  • We report this observation considering the originality of the mode of revelation of the tumour.
  • We insist in addition on the possibility of a conservative treatment.
  • [MeSH-major] Ascites / etiology. Endodermal Sinus Tumor / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Drainage. Female. Humans

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19481364.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


3. Shimizu Y, Komiyama S, Kobayashi T, Nakata K, Iida T: Successful management of endodermal sinus tumor of the ovary associated with pregnancy. Gynecol Oncol; 2003 Mar;88(3):447-50
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful management of endodermal sinus tumor of the ovary associated with pregnancy.
  • BACKGROUND: Pregnancy complicated by endodermal sinus tumor of the ovary has rarely been reported.
  • CASE: A 32-year-old pregnant woman was found to have an ovarian tumor.
  • At 19 weeks of gestation, tumorectomy was performed and a diagnosis of primary endodermal sinus tumor of the ovary (stage Ic) was made.
  • Pregnancy was continued without postoperative chemotherapy.
  • Subsequently, three courses of combination chemotherapy with bleomycin, etoposide, and cisplatin were administered.
  • There was no evidence of recurrence at 27 months after initial treatment.
  • CONCLUSIONS: Successful management of endodermal sinus tumor of the ovary in a pregnant woman is reported.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endodermal Sinus Tumor / drug therapy. Ovarian Neoplasms / drug therapy. Pregnancy Complications, Neoplastic / drug therapy

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12648602.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Aoki Y, Higashino M, Ishii S, Tanaka K: Yolk sac tumor of the ovary during pregnancy: a case report. Gynecol Oncol; 2005 Nov;99(2):497-9
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Yolk sac tumor of the ovary during pregnancy: a case report.
  • BACKGROUND: There is a therapeutic dilemma for the pregnant patient with malignancy requiring chemotherapy.
  • CASE: We had a case of a 30-year-old pregnant woman with a yolk sac tumor who underwent right salpingo-oophorectomy at 22 weeks gestation.
  • Chemotherapy during pregnancy was postponed because of concern with the risks of the chemotherapy to the fetus.
  • Tumor recurrence was confirmed clinically at 34 weeks gestation.
  • She was induced, delivering a healthy baby, and received seven complete chemotherapy courses (cisplatin, etoposide, and peplomycin).
  • Currently, the mother (39 months after last chemotherapy) and child are doing well.
  • CONCLUSION: AFP-L2 may be a sensitive indicator for a yolk sac tumor derived AFP, leading to an earlier detection of tumor recurrence during pregnancy.
  • [MeSH-major] Endodermal Sinus Tumor. Ovarian Neoplasms. Pregnancy Complications, Neoplastic
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Peplomycin / administration & dosage. Plant Lectins. Pregnancy. alpha-Fetoproteins / metabolism


5. Motegi M, Takakura S, Takano H, Tanaka T, Ochiai K: Adjuvant chemotherapy in a pregnant woman with endodermal sinus tumor of the ovary. Obstet Gynecol; 2007 Feb;109(2 Pt2):537-40
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy in a pregnant woman with endodermal sinus tumor of the ovary.
  • BACKGROUND: The administration of chemotherapeutic drugs during pregnancy is rare.
  • We describe a case of malignant ovarian tumor complicating pregnancy.
  • A normal infant was delivered, and no evidence of tumor recurrence was observed.
  • There was no evidence of recurrence observed at 65 months after the initial treatment.
  • CONCLUSION: Although the risk of chemotherapy to the fetus cannot be assessed based on a single case, this experience is encouraging.
  • [MeSH-major] Endodermal Sinus Tumor / diagnosis. Ovarian Neoplasms / diagnosis. Pregnancy Complications, Neoplastic / diagnosis. Prenatal Diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Cesarean Section. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Infant, Newborn. Pregnancy. Pregnancy Trimester, Third. Prenatal Care. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Prenatal Testing.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17267887.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 25
  •  go-up   go-down


6. Benjapibal M, Chaopotong P, Leelaphatanadit C, Jaishuen A: Ruptured ovarian endodermal sinus tumor diagnosed during pregnancy: case report and review of the literature. J Obstet Gynaecol Res; 2010 Oct;36(5):1137-41
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for ovarian endodermal sinus tumor .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ruptured ovarian endodermal sinus tumor diagnosed during pregnancy: case report and review of the literature.
  • Pregnancy complicated by endodermal sinus tumor of the ovary is a very rare event.
  • We present a case report of a pregnant woman with a ruptured primary endodermal sinus tumor of the ovary that was diagnosed at 13 weeks of gestation.
  • After right salpingo-oophorectomy had been performed the patient received four cycles of combination chemotherapy (bleomycin, etoposide, and cisplatin) starting at the 15th week of pregnancy.
  • The patient did not have any evidence of tumor recurrence for 23 months.
  • [MeSH-major] Endodermal Sinus Tumor / diagnosis. Ovarian Neoplasms / diagnosis. Pregnancy Complications, Neoplastic / diagnosis
  • [MeSH-minor] Female. Humans. Ovariectomy. Pregnancy. Rupture, Spontaneous / diagnosis. Rupture, Spontaneous / drug therapy. Rupture, Spontaneous / surgery. Treatment Outcome


7. Thanaboonyawat I, Benjapibal M: A case of ovarian endodermal sinus tumor diagnosed during pregnancy. J Med Assoc Thai; 2008 May;91(5):764-8
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of ovarian endodermal sinus tumor diagnosed during pregnancy.
  • Pregnancy complicated by endodermal sinus tumor of the ovary is extremely rare.
  • The authors present a case report of a pregnant woman with persistent left adnexal mass and subsequently found to have a primary endodermal sinus tumor of the ovary that was diagnosed at 19 weeks of gestation.
  • After left salpingo-oophorectomy had been performed, the patient chose to terminate the pregnancy before the initiation of combination chemotherapy with bleomycin, etoposide, and cisplatin.
  • The response to chemotherapy was not satisfactory.
  • The patient expired after seven cycles of treatment had been completed because of pulmonary fibrosis and the drug toxicity of bleomycin.
  • [MeSH-major] Endodermal Sinus Tumor / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Abortion, Induced. Adult. Antibiotics, Antineoplastic / adverse effects. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Phytogenic / adverse effects. Antineoplastic Agents, Phytogenic / therapeutic use. Bleomycin / adverse effects. Bleomycin / therapeutic use. Cisplatin / adverse effects. Cisplatin / therapeutic use. Etoposide / adverse effects. Etoposide / therapeutic use. Fatal Outcome. Female. Humans. Ovariectomy / methods. Pregnancy. Pregnancy Trimester, First. Pulmonary Fibrosis / chemically induced

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18672645.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. Kang H, Kim TJ, Kim WY, Choi CH, Lee JW, Kim BG, Bae DS: Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor. Gynecol Oncol; 2008 Oct;111(1):106-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor.
  • OBJECTIVE: The aim of this study was to investigate the outcome and reproductive function of patients with ovarian endodermal sinus tumor (EST) after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP).
  • METHODS: Between 1995 and 2006, 1034 patients with the diagnosis of ovarian cancer were treated at a single institution.
  • Among these patients, 51 had a confirmed diagnosis of malignant ovarian germ cell tumor (MOGCT) including 20 cases of EST.
  • We retrospectively reviewed those patients with EST, who received BEP as adjuvant chemotherapy.
  • Of the 15 patients who were treated with fertility-sparing surgery, all had regular menstruation following the completion of adjuvant chemotherapy, and two of these patients had pregnancies with live birth deliveries and no complications.
  • CONCLUSION: In patients with EST, the cumulative high-dose BEP regimen resulted in excellent overall survival and did not seem to impair ovarian function.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Endodermal Sinus Tumor / drug therapy. Endodermal Sinus Tumor / physiopathology. Fertility. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / physiopathology. Ovary / physiopathology
  • [MeSH-minor] Adolescent. Adult. Bleomycin / administration & dosage. Bleomycin / adverse effects. Chemotherapy, Adjuvant. Child. Child, Preschool. Cisplatin / administration & dosage. Cisplatin / adverse effects. Dose-Response Relationship, Drug. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Gynecologic Surgical Procedures / methods. Humans. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18656249.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


9. de La Motte Rouge T, Pautier P, Duvillard P, Rey A, Morice P, Haie-Meder C, Kerbrat P, Culine S, Troalen F, Lhommé C: Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor. Ann Oncol; 2008 Aug;19(8):1435-41
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor.
  • BACKGROUND: Ovarian yolk sac tumor (YST) is a very rare malignancy arising in young women.
  • Chemotherapy has dramatically improved the prognosis.
  • Current treatment consists of surgery followed by bleomycin, etoposide, and cisplatin (BEP) chemotherapy.
  • However, given the rarity of this tumor, ovarian YST-specific survival and outcome after such treatment are not precisely known.
  • PATIENTS AND METHODS: This report concerns prospectively recorded cases that were either treated at Institut Gustave Roussy (Villejuif, France) or referred there for advice about therapy.
  • From 1990 to 2006, 52 patients underwent surgery followed by BEP chemotherapy.
  • Data on patient characteristics, treatment, survival, and fertility outcome were analyzed to assess treatment efficacy and gonadal toxicity after achieving a complete remission.
  • With a median follow-up of 68 months, the overall 5-year survival and disease-free survival rates were 94% and 90%, respectively.
  • CONCLUSIONS: BEP chemotherapy following fertility-sparing surgery is a very effective treatment of ovarian YSTs.

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18408223.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Ayhan A, Taskiran C, Bozdag G, Altinbas S, Altinbas A, Yuce K: Endodermal sinus tumor of the ovary: the Hacettepe University experience. Eur J Obstet Gynecol Reprod Biol; 2005 Dec 1;123(2):230-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endodermal sinus tumor of the ovary: the Hacettepe University experience.
  • OBJECTIVE: The purpose of this study was to evaluate the treatment regimens used for patients with endodermal sinus tumors (EST), and also to examine the prognostic value of surgicopathological variables.
  • STUDY DESIGN: Twenty-two patients treated for pure EST, and seven patients who had mixed germ cell tumors with EST components were included.
  • Initial surgery consisting of surgical staging to achieve optimal debulking was the principal mode of therapy.
  • RESULTS: The median age at the time of diagnosis was 18 (range 8-45).
  • As an adjuvant therapy 18 patients (62%) received platin-based chemotherapy, three patients (10%) had non-platin-based chemotherapy, four patients (14%) had radiotherapy, and four patients (14%) had combined radiotherapy plus non-platin-based chemotherapy.
  • Platin-based chemotherapy achieved significant survival benefit (P = 0.03 and P < 0.001, respectively).
  • There was no significant survival difference with respect to age, histology, and tumor size.
  • CONCLUSION: Fertility-sparing surgery with a postoperative platin-based combination chemotherapy should be the selected mode of treatment.
  • [MeSH-major] Endodermal Sinus Tumor / therapy. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Child. Combined Modality Therapy. Female. Gynecologic Surgical Procedures. Hospitals, University. Humans. Middle Aged. Neoplasm Staging. Platinum Compounds / therapeutic use. Prognosis. Retrospective Studies. Survival Analysis. Turkey

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16026921.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Platinum Compounds
  •  go-up   go-down


11. Lopez JM, Malpica A, Deavers MT, Ayala AG: Ovarian yolk sac tumor associated with endometrioid carcinoma and mucinous cystadenoma of the ovary. Ann Diagn Pathol; 2003 Oct;7(5):300-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian yolk sac tumor associated with endometrioid carcinoma and mucinous cystadenoma of the ovary.
  • The clinicopathologic and immunohistochemical findings of an unusual case of ovarian yolk sac tumor associated with endometrioid carcinoma and mucinous cystadenoma of the ovary are reported.
  • The tumor was detected in a 51-year-old postmenopausal woman who presented with abdominal swelling and a pelvic mass.
  • The tumor was confined to the right ovary and measured 16.0 cm in greatest dimension.
  • Microscopic examination revealed that the tumor had a yolk sac component associated with an endometrioid carcinoma, grade I, and a mucinous cystadenoma.
  • Immunoperoxidase studies showed that the yolk sac component stained diffusely with a cytokeratin cocktail and was focally positive for alpha-fetoprotein.
  • In contrast, the endometrioid carcinoma stained positive for keratin 7 in addition to the cytokeratin cocktail, but was negative for alpha-fetoprotein.
  • After surgery, the patient received three cycles of chemotherapy.
  • However, the disease progressed and the patient died 10 months after the diagnosis of the ovarian tumor.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Cystadenoma, Mucinous / pathology. Endodermal Sinus Tumor / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Combined Modality Therapy. Female. Gynecologic Surgical Procedures. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasms, Multiple Primary. Postmenopause

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14571433.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 17
  •  go-up   go-down


12. Manchana T, Sirisabya N, Lertkhachonsuk R, Tresukosol D: Transient cortical blindness during chemotherapy (PVB) for ovarian germ cell tumor. J Med Assoc Thai; 2006 Aug;89(8):1265-8
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient cortical blindness during chemotherapy (PVB) for ovarian germ cell tumor.
  • A 17 year-old female with stage IIIc endodermal sinus tumor of the ovary developed transient cortical blindness and severe hypertension after 5 cycles of PVB regimen consisting of cisplatin, vinblastine and bleomycin.
  • Her visual acuity and blood pressure completely recovered within a few days after supportive treatment with antihypertensive drug.
  • Most reports suggested that this rare toxicity was from cisplatin therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Bleomycin / adverse effects. Blindness, Cortical / chemically induced. Brain Diseases / chemically induced. Brain Diseases / pathology. Cisplatin / administration & dosage. Cisplatin / adverse effects. Endodermal Sinus Tumor / drug therapy. Ovarian Neoplasms / drug therapy. Vinblastine / administration & dosage. Vinblastine / adverse effects
  • [MeSH-minor] Adolescent. Female. Humans. Magnetic Resonance Imaging. Neoplasm Staging


13. Erdemoglu E, Ozen S: Ovarian gonodoblastoma with yolk sac tumor in a young 46, XX female: case report. Eur J Gynaecol Oncol; 2007;28(6):516-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian gonodoblastoma with yolk sac tumor in a young 46, XX female: case report.
  • BACKGROUND: Gonodoblastomas with ovarian germ cell tumors (OGCTs) other than dysgerminoma are very unusual.
  • This is the first case report of a pure endodermal sinus tumor of the ovary with gonodoblastoma in a 46 XX, female.
  • Fertility sparing surgery was undertaken and revealed a Stage IA endodermal sinus tumor and gonodoblastoma in the same ovary.
  • The patient refused chemotherapy and was followed-up for six months without disease.
  • Tumor markers and immunohistochemical examination may help in the diagnosis of these OGCTs with gonodoblastoma.
  • [MeSH-major] Endodermal Sinus Tumor / genetics. Gonadoblastoma / genetics. Ovarian Neoplasms / genetics

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18179152.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


14. Jeyakumar A, Chalas E, Hindenburg A: Sustained complete remission in a patient with platinum-resistant ovarian yolk sac tumor. Gynecol Oncol; 2001 Sep;82(3):578-80
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained complete remission in a patient with platinum-resistant ovarian yolk sac tumor.
  • BACKGROUND: Yolk sac tumors of the ovary are generally very responsive to chemotherapy; however, they are difficult to manage in the setting of platinum resistance where treatment options are limited and outcomes are poorer.
  • CASE: We present a 39-year-old woman who had a platinum-resistant yolk sac ovarian tumor.
  • CONCLUSION: The combination of docetaxel, gemcitabine, and thalidomide might be an active regimen for platinum-resistant ovarian nondysgerminomas and further investigation of this combination is warranted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endodermal Sinus Tumor / drug therapy. Ovarian Neoplasms / drug therapy. Taxoids
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Resistance, Neoplasm. Female. Humans. Paclitaxel / administration & dosage. Paclitaxel / analogs & derivatives. Thalidomide / administration & dosage

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11520160.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 4Z8R6ORS6L / Thalidomide; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


15. Ghaemmaghami F, Ayatollahi H, Daneshbodi B, Azmoodeh FA: Unusual location of ovarian mixed germ cell tumor. Int J Gynecol Cancer; 2005 Sep-Oct;15(5):979-83
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual location of ovarian mixed germ cell tumor.
  • Intra-abdominal unusual location of mixed germ cell tumor of ovary, which consisted of endodermal sinus tumor and immature teratoma components, has been reported.
  • Patient was a 21-year-old girl with a chief complaint of abdominal pain and mass.
  • Ultrasound and computed tomography scan showed lobulated cystic mass.
  • Laparotomy was performed, and due to specific localization, in which tumor localized as a tumoral bridge between two ovaries, we just performed maximal fertility-sparing surgery by preserving ovaries, tubes, and uterus.
  • After that, four courses of chemotherapy (bleomycin, etoposide, and cis-platinum) were done to cure her.
  • The alfa-fetoprotein became negative after three courses of chemotherapy, and she is under observation for the time being.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian germ cell tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16174255.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Arora M, Shrivastav RK, Jaiprakash MP: A rare germ-cell tumor site: vaginal endodermal sinus tumor. Pediatr Surg Int; 2002 Sep;18(5-6):521-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare germ-cell tumor site: vaginal endodermal sinus tumor.
  • Malignant germ-cell tumors (MGCT) are rare tumors of childhood accounting for less than 3% of pediatric malignancies.
  • Endodermal sinus tumor (EST) forms the most common histologic subtype of MGCT.
  • A 9-month-old female was admitted with a short history of vaginal bleeding, a mass protruding from the vagina, and difficulty in passing urine.
  • The serum alpha-fetoprotein (AFP) was elevated partial vaginectomy was done and the tumor was excised in toto.
  • In females, it is usually encountered in the ovary.
  • EST of the vagina is a rare, highly malignant GCT that exclusively involves children less than 3 years of age.
  • The diagnosis is based on histology and raised AFP.
  • Partial vaginectomy with combination chemotherapy is the most recommended line of treatment.
  • The surgery eradicates local tumor cells and makes subsequent chemotherapy more effective.
  • Simple tumor excision is not sufficient, as residual tumor cells induce early recurrence and make chemotherapy ineffective.
  • The serum AFP level is a useful marker for diagnosis and monitoring the recurrence of vaginal EST in infants.
  • [MeSH-major] Endodermal Sinus Tumor / surgery. Vaginal Neoplasms / surgery
  • [MeSH-minor] Female. Humans. Infant. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12415399.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Cyganek A, Ejmocka-Ambroziak A, Wiczyńska-Zajac A, Marianowski L: [Ovarian endodermal sinus tumor associated with pregnancy--a case report]. Ginekol Pol; 2002 Apr;73(4):408-11
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian endodermal sinus tumor associated with pregnancy--a case report].
  • An ovarian endodermal sinus tumor was found in a 29-years old patient with a 32-week intrauterine gestation.
  • She received caesarean section, conservative surgery and three courses of combination chemotherapy.
  • She died 6 months after the diagnosis.
  • [MeSH-major] Endodermal Sinus Tumor. Ovarian Neoplasms. Pregnancy Complications, Neoplastic
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fatal Outcome. Female. Humans. Pregnancy

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12152296.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


18. Guillem V, Poveda A: Germ cell tumours of the ovary. Clin Transl Oncol; 2007 Apr;9(4):237-43
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germ cell tumours of the ovary.
  • Germinal cell tumours represent only 2-5% of all cancers of the ovary.
  • However, the characteristics of the tumour and the patients have some special qualities as high rates of healing goes together with a strong desire to keep fertility intact because this condition occurs in female children and adolescent girls.
  • Neither the prognosis nor the treatment of these tumours is homogeneous; the low incidence is the reason it is hard to develop prospective studies for establishing prognostic factors and specific treatments.
  • The introduction of adjuvant chemotherapy into initial surgery has improved the prognosis of these patients.
  • The surgical treatment demands the application of the same principles seen in cytoreduction surgery of epithelial cancers of the ovary (maximum possible cytoreduction), though in many cases hysterectomy and double adnexectomy may be obviated.
  • In view of the rarity of these tumours, it is advisable to work within cooperative groups that may have subgroups for the treatment of rare tumours.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal. Ovarian Neoplasms
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor. Carcinoma, Embryonal / diagnosis. Carcinoma, Embryonal / drug therapy. Carcinoma, Embryonal / pathology. Child. Choriocarcinoma / diagnosis. Choriocarcinoma / drug therapy. Choriocarcinoma / pathology. Chorionic Gonadotropin, beta Subunit, Human. Dysgerminoma / diagnosis. Dysgerminoma / drug therapy. Dysgerminoma / pathology. Endodermal Sinus Tumor / diagnosis. Endodermal Sinus Tumor / drug therapy. Endodermal Sinus Tumor / pathology. Female. Humans. Neoplasm Staging. Ovary / pathology. Prognosis. Randomized Controlled Trials as Topic. Teratoma / diagnosis. Teratoma / drug therapy. Teratoma / pathology. World Health Organization. alpha-Fetoproteins

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17462976.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins
  • [Number-of-references] 49
  •  go-up   go-down


19. Rzepka-Górska I, Błogowska A, Zajaczek S, Zielińska D: [Germinal cell tumors in young and adolescent girls]. Ginekol Pol; 2003 Sep;74(9):840-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Germinal cell tumors in young and adolescent girls].
  • OBJECTIVE: Germ cell tumours are the most common ovarian tumours in childhood and adolescence.
  • This diverse group of tumours derives from germ cells.
  • DESIGN: The aim of this work is presentation of germ cell tumours in the material from our clinic with characteristic clinical features, the scope of operation and effects of many years of observation.
  • MATERIALS AND METHODS: We treated 109 girls with germ cell tumours of the ovary: 13 had malignant tumours: there were 7 patients with dysgerminomas, 2 with endodermal sinus tumour of the ovary, 3 with immature teratomas, 1 with carcinoma embryonale.
  • There can be problems with diagnosis of the syndrome, because developmental features imitate the onset of normal puberty.
  • It must be suggested that patients of stage I who wish to preserve childbearing function may be treated with unilateral salpingoophorectomy and adjuvant chemotherapy.
  • Monitoring of the treatment is connected with measurement of biochemical markers.
  • Some of these markers are useful for monitoring of response to therapy.
  • Cytological smears and biopsy specimens from the remaining ovary, peritoneum and subdiaphragmatic area should be obtained laparoscopically.
  • CONCLUSIONS: The sift ultrasonographic investigations can be helpful in the early diagnosis of germ cell tumours of the ovary in girls.
  • Fertility sparing operative treatment is preferred when karyotype is normal.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Germ Cell and Embryonal / therapy. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / blood. Child. Combined Modality Therapy. Dysgerminoma / pathology. Dysgerminoma / therapy. Endodermal Sinus Tumor / pathology. Endodermal Sinus Tumor / therapy. Female. Germinoma / pathology. Germinoma / therapy. Gonadoblastoma / pathology. Gonadoblastoma / therapy. Gonadotropins / blood. Gonadotropins / genetics. Humans. Poland. Risk Factors. Teratoma / pathology. Teratoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14674134.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Gonadotropins
  •  go-up   go-down


20. Robova H, Rob L, Hrehorcak M, Zoban P, Prusa R: Endodermal sinus tumor diagnosed in pregnancy: a case report. Int J Gynecol Cancer; 2007 Jul-Aug;17(4):914-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endodermal sinus tumor diagnosed in pregnancy: a case report.
  • Pure endodermal sinus tumor (EST) of the ovary is an uncommon germ cell tumor characterized by rapid growth.
  • The case of a 34-year-old woman with EST stage IC diagnosed in the 22nd week of gestation is presented.
  • Further, three cycles of combination chemotherapy (cisplatin, bleomycin, and etoposide) were administered.
  • The child showed normal laboratory, pediatric, and neurologic examination at the time of discharge from hospital and during the first and second years of her life.
  • We conclude that the prognosis of EST is very good if patient receives adjuvant therapy.
  • [MeSH-major] Endodermal Sinus Tumor / diagnosis. Endodermal Sinus Tumor / therapy. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / therapy. Pregnancy Complications, Neoplastic / diagnosis. Pregnancy Complications, Neoplastic / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Etoposide / administration & dosage. Female. Humans. Infant, Newborn. Pregnancy

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17635618.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


21. Ayas S, Aköz I, Eskicirak E, Karateke A, Bozoklu O: A case of endodermal sinus tumor associated with the first pregnancy and successful management of the second pregnancy: a case report and review of the literature. Eur J Gynaecol Oncol; 2007;28(2):155-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of endodermal sinus tumor associated with the first pregnancy and successful management of the second pregnancy: a case report and review of the literature.
  • BACKGROUND: Pregnancy complicated by endodermal sinus tumor (EST) of the ovary has rarely been reported.
  • CASE: A huge ovarian EST causing bowel obstruction was found in a 22-year-old patient at 34 weeks of gestation.
  • Abnormally high alpha-fetoprotein (AFP) levels suggested a malignant germ cell tumor of the ovary.
  • The patient was submitted to cesarean section and fertility sparing surgery, and then received four courses of combination chemotherapy.
  • There was no evidence of recurrence 19 months after initial treatment but transvaginal ultrasound (US) evaluation showed an intrauterine pregnancy of six weeks.
  • CONCLUSIONS: Successful outcome of a second pregnancy is possible after treatment with fertility sparing surgery and combination chemotherapy for an endodermal sinus tumor associated with a first pregnancy.
  • [MeSH-major] Endodermal Sinus Tumor / diagnosis. Endodermal Sinus Tumor / drug therapy. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / drug therapy. Pregnancy Complications, Neoplastic / diagnosis. Pregnancy Complications, Neoplastic / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Pregnancy. Pregnancy Outcome. Pregnancy Trimester, Third. Treatment Outcome. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17479685.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  • [Number-of-references] 34
  •  go-up   go-down


22. Moodley M, Moodley J: Ovarian germ cell malignancy and human immunodeficiency virus (HIV) infection: a case report. Int J Gynecol Cancer; 2003 Jul-Aug;13(4):541-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian germ cell malignancy and human immunodeficiency virus (HIV) infection: a case report.
  • The occurrence of germ cell tumors in patients with human immunodeficiency virus (HIV) infection has not been previously reported.
  • The approach to management as well as the role of adjuvant radiotherapy and chemotherapy is problematic as many of these therapies are toxic.
  • The presentation, management, and outcome of ovarian endodermal sinus tumor in a HIV-infected patient is reported.
  • [MeSH-major] Germinoma / complications. Germinoma / therapy. HIV Infections / complications. Ovarian Neoplasms / complications. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adolescent. Biopsy, Needle. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Immunohistochemistry. Ovariectomy / methods. Radiotherapy, Adjuvant. Risk Assessment. Treatment Outcome

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12911735.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Shen K, Lang J, Huang H: [Treatment of childhood genital malignancies]. Zhonghua Fu Chan Ke Za Zhi; 2001 Jun;36(6):360-3
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of childhood genital malignancies].
  • OBJECTIVE: To present the clinical profile and the result of treatment in childhood genital malignancies.
  • METHODS: Twenty seven childhood patients (< 12 years) with genital malignancies diagnosed and treated in Peking Union Medical College hospital were analyzed retrospectively focusing on the clinical characteristics and outcome of the treatment.
  • RESULTS: Patients ranged in age from 2 to 12 years with mean 6.5 years at diagnosis.
  • Of the 27 patients, 23 had ovarian malignancies including 21 (77.8%) germ cell tumor.
  • Four of the patients had extragonadal tumors with 2 endodermal sinus tumor of the vagina, and 2 embryonic rhabdomysarcoma.
  • In ovarian malignancies, abdominal mass and abdominal pain were main clinical features accounting for 77.8% and 74.1% respectively.
  • In vaginal malignancies, vaginal bleeding and polypoid tumor of the vagina were important clinical manifestations.
  • 91.3% (21/23) of the patients underwent only unilateral salpingo-oophorectomy with preservation of contralateral ovary and the uterus.
  • Childhood genital malignancies were very sensitive to the chemotherapy.
  • Postoperative vincristine, actinomycine, cyclophosphamide (VAC) or cisplatine, vincristine, blyomycine (PVB) chemotherapy was individualized according to the tumor site, International Federation of Gynecology and obstetrics stage and histopathology.
  • Survival rate in our series was 71.4% during the follow-up time (mean 47.4 months).
  • CONCLUSIONS: Malignant germ cell tumor of the ovary is the most common tumor in the childhood genital malignancies.
  • Principle of primary surgery is preservation of fertility and chemotherapy is also considered as a very important treatment modality.
  • [MeSH-major] Genital Neoplasms, Female / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Child. Child, Preschool. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Drug Administration Schedule. Female. Humans. Retrospective Studies. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11783136.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; PVB protocol; VAC protocol
  •  go-up   go-down


24. Bahri I, Boudawara T, Khabir A, Beyrouti MI, Frikha M, Jlidi R: [Clear cell carcinoma of the ovary simulating a yolk sac tumor]. Ann Pathol; 2003 Apr;23(2):165-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clear cell carcinoma of the ovary simulating a yolk sac tumor].
  • [Transliterated title] Carcinome à cellules claires de l'ovaire simulant une tumeur vitelline.
  • Clear cell carcinoma (CCC) of the ovary is uncommon.
  • In young patients, this tumor may simulate a yolk sac tumor.
  • In this case, the morphologic distinction between these tumors is often difficult but the immunohistochemical staining for CA125 and alpha foeto protein (AFP) and the response to chemotherapy are particularly helpful to resolve this problem of differential diagnosis.
  • We report a case of a 17 year old patient who was operated for a tumor of the right ovary.
  • The diagnosis of a yolk sac tumor was first suggested.
  • However, because of the non response to chemotherapy, a second laparotomy was performed; the definitive pathologic examination concluded to the diagnosis of a CCC of the ovary.
  • Our objective about this particular case is to discuss the anatomoclinical aspects of the CCC of the ovary and to prove the role of immunohistochemistry in the differential diagnosis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Endodermal Sinus Tumor. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. CA-125 Antigen / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12843973.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / alpha-Fetoproteins
  •  go-up   go-down


25. Lee KH, Lee IH, Kim BG, Nam JH, Kim WK, Kang SB, Ryu SY, Cho CH, Choi HS, Kim KT, Korean Gynecologic Oncology Group: Clinicopathologic characteristics of malignant germ cell tumors in the ovaries of Korean women: a Korean Gynecologic Oncology Group Study. Int J Gynecol Cancer; 2009 Jan;19(1):84-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic characteristics of malignant germ cell tumors in the ovaries of Korean women: a Korean Gynecologic Oncology Group Study.
  • We evaluated the clinicopathologic characteristics of malignant germ cell tumors in the ovaries of South Korean women and determined the prognostic factors affecting recurrence.
  • Histologically, immature teratoma was the most common tumor type (n = 68), followed by dysgerminoma (n = 54), endodermal sinus tumor (n = 38), mixed form (n = 24), and choriocarcinoma (n = 12).
  • Postoperative chemotherapy was administered in 166 patients, and the most common regimen was bleomycin, etoposide, and cisplatin (n = 120).
  • Recurrence was observed in 13 patients (6.8%) and was influenced by the stage of the tumor and patient age (>40 years).
  • The results of this study demonstrate that most malignant germ cell tumors of the ovary in Korean women are detected in the early stage and have excellent survival outcomes with conservative operation and platinum-based chemotherapy.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Korea. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19258947.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Lee JK; Park JJ; Cha MS; Kim JH; Lee JM; Park SY; Kim SC; Lee SK
  •  go-up   go-down


26. Kamoi S, Ohaki Y, Mori O, Okada S, Seto M, Matsushita N, Kawamura T, Araki T: A case of ovarian endometrioid adenocarcinoma with yolk sac tumor component in a postmenopausal woman. APMIS; 2002 Jun;110(6):508-14
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of ovarian endometrioid adenocarcinoma with yolk sac tumor component in a postmenopausal woman.
  • The co-existence of an endometrioid adenocarcinoma with an ovarian yolk sac tumor is very rare.
  • A 54-year-old postmenopausal woman with a 6-month history of progressive abdominal distension was seen at our hospital.
  • MR imaging revealed a large cyst with a solid intramural node.
  • At laparotomy, a large tumor approximately 20 cm in diameter was found to occupy the abdominal cavity, adhering to the swollen appendix and part of the omentum.
  • Microscopically, foci of endometrioid adenocarcinoma together with a yolk sac tumor component were observed within a large endometriotic cyst.
  • Since the tumor was clinically staged 1c, the patient was given 500 mg of intraperitoneal carboplatin postoperatively, followed by five courses of combination chemotherapy consisting of cisplatin, etoposide and peplomycin at 4-week intervals.
  • In contrast to a very poor prognosis of this tumor in previously reported cases, our patient showed no sign of recurrence during a 21-month follow-up period.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endodermal Sinus Tumor / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Antigens, Tumor-Associated, Carbohydrate / analysis. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Middle Aged. Postmenopause. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12193212.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins
  •  go-up   go-down


27. Nawa A, Obata N, Kikkawa F, Kawai M, Nagasaka T, Goto S, Nishimori K, Nakashima N: Prognostic factors of patients with yolk sac tumors of the ovary. Am J Obstet Gynecol; 2001 May;184(6):1182-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors of patients with yolk sac tumors of the ovary.
  • OBJECTIVE: Our purpose was to evaluate the prognostic factors in yolk sac tumors of the ovary.
  • STUDY DESIGN: We performed a retrospective review of 47 patients with yolk sac tumors of the ovary from 1979 to 1997.
  • RESULTS: Twenty-two patients had pure yolk sac tumors and 25 had germ cell tumors with yolk sac tissue as a component of the disease.
  • All patients who did not respond to chemotherapy died of this disease within 36 months of the first treatment.
  • Chemotherapy regimens that included cisplatin gave better results than those without cisplatin (P <.05).
  • The difference in prognosis was significant in cases in which the size of residual tumor was <2 cm in diameter (P <.01) and in cases in which ascites was either absent or <100 mL in volume (P <.05).
  • Coexistence of other components of ovarian germ cell tumors in histologic specimens, preoperative serum alpha-fetoprotein level, fertility-sparing surgery, dissection of intrapelvic nodes, and p53 status had no significant correlation with the prognosis in this study.
  • CONCLUSIONS: Staging and tumor-reductive surgery strongly affected the prognosis of this disease.
  • Tumor-reductive surgery is advisable when ascites is minimal.
  • Cisplatin-based chemotherapy after surgery was superior to chemotherapy without cisplatin; however, p53 status seemed to have no impact on chemosensitivity in yolk sac tumors of the ovary.
  • [MeSH-major] Endodermal Sinus Tumor / physiopathology. Ovarian Neoplasms / physiopathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ascites / metabolism. Cisplatin / therapeutic use. Female. Humans. Mortality. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11349186.001).
  • [ISSN] 0002-9378
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


28. El-Lamie IK, Shehata NA, Abou-Loz SK, El-Lamie KI: Conservative surgical management of malignant ovarian germ cell tumors: the experience of the Gynecologic Oncology Unit at Ain Shams University. Eur J Gynaecol Oncol; 2000;21(6):605-9
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative surgical management of malignant ovarian germ cell tumors: the experience of the Gynecologic Oncology Unit at Ain Shams University.
  • PURPOSE: To evaluate the role of extended surgical staging in patients with malignant ovarian germ cell tumors in the presence of cisplatinum-based combination chemotherapy.
  • MATERIALS & METHODS: 16 patients aged between 13 and 40 years (mean 20.5) diagnosed and treated for malignant ovarian germ cell tumors at the Gynecologic Oncology Unit.
  • RESULTS: Six patients were diagnosed with dysgerminoma, six with immature teratoma and four with endodermal sinus tumor.
  • However, the remaining nine cases were referred to the unit, six after having unilateral salpingo-oophorectomy and no surgical staging, one patient after total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH+BSO), and one with recurrent dysgerminoma in the retroperitoneum and mediastinum following suboptimal treatment.
  • None of these cases were surgically re-explored and all including the first six cases were given the standard BEP chemotherapy for 4-6 courses (mean 5.8).
  • All patients are alive without any evidence of disease recurrence except for one patient with a stage IIIA immature teratoma who had a local and distant recurrence and is undergoing second-line chemotherapy.
  • All patients have their menstrual function preserved except for three patients; one having 46,XX pure gonadal dysgenesis with a preoperative FSH level of 120 U/l and the eldest two patients having a TAH+BSO as they had completed their families.
  • CONCLUSION: In view of the high chemosensitivity and curability of ovarian germ cell tumors and their occurrence in young patients, every effort should be made to preserve one ovary and the uterus for future reproduction even in advanced cases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Germinoma / drug therapy. Germinoma / surgery. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Egypt. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Neoplasm Staging. Reoperation. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11214621.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


29. Dede M, Pabuccu R, Yagci G, Yenen MC, Goktolga U, Gunhan O: Extragonadal yolk sac tumor in pelvic localization. A case report and literature review. Gynecol Oncol; 2004 Mar;92(3):989-91
Genetic Alliance. consumer health - Yolk sac tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extragonadal yolk sac tumor in pelvic localization. A case report and literature review.
  • BACKGROUND: Yolk sac tumor (YST) is a rare neoplasm that usually arises in the testis or ovary.
  • We report a case of extragonadal yolk sac tumor located in the pelvic area.
  • CASE: A 33-year-old woman was admitted with a history of abdominal pain and distension.
  • Exploration findings revealed an extragonadal mass and she was treated with left pelvic mass extirpation, bilateral ovarian wedge resection, and reconstruction.
  • Histological evaluation of the specimen exhibited typical patterns of endodermal sinus tumor and stained for a-fetoprotein and cytokeratin.
  • Four courses of bleomycin, etoposide, and cisplatin combination chemotherapy repeated every 3 weeks were added to therapy and she has remained free of disease for 6 months after completion of the therapy.
  • [MeSH-major] Endodermal Sinus Tumor / pathology. Pelvic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14984973.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 11
  •  go-up   go-down


30. Haibin Z, Yue J, Yaxian X: Primary yolk sac tumor of the omentum: a case report and literature review. Eur J Gynaecol Oncol; 2010;31(6):682-4
Genetic Alliance. consumer health - Yolk sac tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary yolk sac tumor of the omentum: a case report and literature review.
  • BACKGROUND: Yolk sac tumor (YST) is the second most common malignant ovarian germ cell tumor, while a YST arising in the omentum is an exceedingly rare malignancy.
  • CASE: A 44-year-old woman was admitted with a history of abdominal distension of a month's duration.
  • Explorative findings revealed a large omental mass with a small implantation on the surface of the left ovary.
  • The patient was treated with total abdominal hysterectomy with bilateral salpingo-oophorectomy and infracolic omentectomy followed by four cycles of bleomycin, etoposide, and cisplatin combination chemotherapy.
  • She has remained free of the disease for seven months after completion of therapy.
  • The case of omental YST must be seriously considered once the tumor shows omentum thickening with elevated AFP serum levels.
  • [MeSH-major] Endodermal Sinus Tumor / diagnosis. Endodermal Sinus Tumor / therapy. Omentum / surgery. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Female. Humans. Hysterectomy. Ovariectomy. Peritoneum / pathology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21319517.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  •  go-up   go-down


31. Nishio S, Ushijima K, Fukui A, Fujiyoshi N, Kawano K, Komai K, Ota S, Fujiyoshi K, Kamura T: Fertility-preserving treatment for patients with malignant germ cell tumors of the ovary. J Obstet Gynaecol Res; 2006 Aug;32(4):416-21
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fertility-preserving treatment for patients with malignant germ cell tumors of the ovary.
  • AIM: The aim of this study was to investigate whether fertility preservation influences the clinical outcome in patients with malignant germ cell tumors of the ovary (MGCTO).
  • Thirty-five patients were included in the study, 14 with immature teratoma, 11 with dysgerminoma, eight with endodermal sinus tumor, and two with mixed germ cell tumor.
  • As the adjuvant treatment, 30 patients received chemotherapy, while five patients did not receive any chemotherapy.
  • She was 13 years old with a stage IV endodermal sinus tumor.
  • CONCLUSIONS: Irrespective of the stage of the disease, conservative surgery and adjuvant chemotherapy for MGCTO can achieve a favorable outcome in terms of survival and fertility.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / surgery. Ovarian Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16882268.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


32. Hong DG, Chong GO, Seong WJ, Lee YS, Cho YL, Park JY, Chae JM, Park IS: A case of ovarian endometrioid adenocarcinoma with yolk sac tumor in a 35-year-old woman. Eur J Gynaecol Oncol; 2010;31(4):471-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of ovarian endometrioid adenocarcinoma with yolk sac tumor in a 35-year-old woman.
  • Ovarian yolk sac tumor (YST) is a malignant ovarian neoplasm differentiated from primordial germ cells that occur in young age, while endometrioid carcinoma (ECA) is a müllerian epithelial tumor that usually occurs in older patients.
  • The coexistence of an ovarian ECA and YST component is very rare.
  • We present a case of a simultaneous ECA and a YST component in a 35-year-old woman.
  • After completion of four courses of BEP chemotherapy, two courses of taxane and carboplatin chemotherapy were added.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endodermal Sinus Tumor / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20882900.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  •  go-up   go-down


33. Yang WP, Zou Y, Huang CS, Zhang SZ, Xiao Q, Dai KL, Zhong HS, Xiong XJ: [Clinicopathologic and prognostic study of pediatric immature teratoma]. Zhonghua Bing Li Xue Za Zhi; 2007 Oct;36(10):666-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Amongst the 39 cases studied, 12 arose in the sacrococcygeal region, 12 in testis, 5 in retroperitoneum, 4 in ovary, 4 in abdomen and 2 in mediastinum.
  • Seven of the cases contained foci of yolk sac tumor.
  • Immature neuroepithelial features used in histologic grading included the presence of primitive neural tubules, immature rosettes, undifferentiated neuroblastoma cells and primitive neuroectodermal structures.
  • Three of them, including 2 cases with histologic grade 3 (with or without yolk sac tumor component), recurred after operation.
  • On the other hand, p27 overexpression shows little correlation with tumor grade.
  • Sacrococcygeal immature teratoma occurring in patients younger than 1 year old and with low histologic grade do not require postoperative chemotherapy if the tumor is completely excised.
  • Similarly, for testicular immature teratoma occurring in patients below 1 year of age, regardless of tumor grading, need no adjunctive therapy.
  • On the other hand, ovarian immature teratoma with high histologic grade requires postoperative chemotherapy, regardless of age of the patients.
  • The presence of microscopic foci of yolk sac tumor is a useful predictor of recurrence in pediatric immature teratoma.
  • [MeSH-major] Ovarian Neoplasms / pathology. Retroperitoneal Neoplasms / pathology. Teratoma / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adolescent. Cyclin D1 / metabolism. Endodermal Sinus Tumor / drug therapy. Endodermal Sinus Tumor / metabolism. Endodermal Sinus Tumor / pathology. Endodermal Sinus Tumor / surgery. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Ki-67 Antigen / metabolism. Male. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / metabolism. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / surgery. Neoplasm Recurrence, Local. Neoplasm Staging. Proliferating Cell Nuclear Antigen / metabolism. Sacrococcygeal Region. Survival Rate. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18194599.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 0 / alpha-Fetoproteins; 0 / p27 antigen; 136601-57-5 / Cyclin D1
  •  go-up   go-down


34. Cicin I, Saip P, Guney N, Eralp Y, Ayan I, Kebudi R, Topuz E: Yolk sac tumours of the ovary: evaluation of clinicopathological features and prognostic factors. Eur J Obstet Gynecol Reprod Biol; 2009 Oct;146(2):210-4
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Yolk sac tumours of the ovary: evaluation of clinicopathological features and prognostic factors.
  • OBJECTIVE: To evaluate the clinicopathological prognostic features, factors and outcomes of chemotherapy in ovarian yolk sac tumours (YST).
  • STUDY DESIGN: We reviewed the medical records of 32 women with ovarian YST treated from 1990 to 2006 at two centres.
  • The most common symptoms at diagnosis included abdominal swelling or mass (72%) and abdominopelvic pain (62%).
  • The location of the tumour was bilateral in 2 cases.
  • Of 32 patients who received postoperative chemotherapy, 27 were treated with a bleomycin/etoposide/cisplatin (BEP) regimen.
  • Ten (31%) patients suffered from a recurrence of the disease with a median time to recurrence of 8 months (range, 6-28 months).
  • While age, histology (mixed vs. pure), stage, tumour size, ascites, and marker levels were not found as prognostic factors, the presence of residual tumour (P=0.014) and BEP chemotherapy (P=0.016) were significant prognostic factors in univariate analysis.
  • CONCLUSIONS: In patients with ovarian YST, fertility-sparing surgery is as effective as radical surgery.
  • In these tumours, adjunctive therapeutic modalities to eradicate intra-abdominal disease and effective salvage therapy strategies are needed.
  • [MeSH-major] Endodermal Sinus Tumor / diagnosis. Endodermal Sinus Tumor / pathology. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Child. Cisplatin / administration & dosage. Combined Modality Therapy. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Hysterectomy. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Ovariectomy. Prognosis. Retrospective Studies. Risk Factors. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19419810.001).
  • [ISSN] 1872-7654
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Ireland
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


35. Bakri YN, Ezzat A, Akhtar, Dohami, Zahrani: Malignant germ cell tumors of the ovary. Pregnancy considerations. Eur J Obstet Gynecol Reprod Biol; 2000 May;90(1):87-91
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant germ cell tumors of the ovary. Pregnancy considerations.
  • OBJECTIVE: To study the pregnancy association and malignant germ cell tumors of the ovary with regard to its effects on tumor prognosis.
  • STUDY DESIGN: : Seventy-five patients with malignant germ cell tumors of the ovary treated at the King Faisal Specialist Hospital-Research Center (KFSH-RC) Riyadh, Kingdom of Saudi Arabia between January 1976 and December 1992, were reviewed.
  • Data was retrieved from the medical records and the database of ovarian tumor pathology.
  • Patients with tumor/pregnancy association were identified and correlation with obstetrical outcome and tumor prognosis analyzed.
  • Patients who conceived after treatment were identified and their reproductive outcome described.
  • RESULTS: Malignant germ cell tumor was associated with pregnancy in a group of ten patients.
  • Possible tumor effects upon pregnancy in this group included operative delivery by caesarean section (n=3), mid-trimester termination (n=2), spontaneous abortion (n=1).
  • Four patients had normal vaginal birth with no apparent tumor effects upon pregnancy.
  • Pregnancy did not seem to influence the tumor prognosis of pure dysgerminoma (n=6), however, two patients with non-dysgerminomatous germ cell tumor (one endodermal sinus tumor and one immature teratoma) died of rapidly progressive disease during the second trimester.
  • Two patients with advanced (stage IIIC) disease concurrent with pregnancy (one pure dysgerminoma and one mixed germ cell tumor), had normal fetal outcomes and achieved long-term survival.
  • Amongst the 22 patients who planned to conceive after conservative surgery, with or without post-operative adjuvant chemotherapy, 12 conceived (12/22) and achieved a total of 20 pregnancies.
  • CONCLUSIONS: Our findings suggest that, (1) The association of pure dysgerminoma and pregnancy did not adversely affect the tumor prognosis or fetal outcome.
  • However, the question remains as to whether pregnancy worsened the prognosis of non-dysgerminomatous germ cell tumors. (2) Recent platinum-based regimens of multiagent chemotherapy for germ cell tumors did not seem to affect fertility potential.
  • [MeSH-major] Germinoma / pathology. Ovarian Neoplasms / pathology. Pregnancy Complications, Neoplastic / pathology
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Middle Aged. Neoplasm Staging. Pregnancy. Pregnancy Outcome. Reproductive History

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10767517.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] IRELAND
  •  go-up   go-down


36. Bafna UD, Umadevi K, Kumaran C, Nagarathna DS, Shashikala P, Tanseem R: Germ cell tumors of the ovary: is there a role for aggressive cytoreductive surgery for nondysgerminomatous tumors? Int J Gynecol Cancer; 2001 Jul-Aug;11(4):300-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germ cell tumors of the ovary: is there a role for aggressive cytoreductive surgery for nondysgerminomatous tumors?
  • Thirty-three patients with germ cell tumor of the ovary were seen at Kidwai Memorial Institute of Oncology (KMIO), Bangalore, between 1996 and 1999.
  • Twelve patients had endodermal sinus tumor (EST), 11 dysgerminoma, seven mixed germ cell tumor, and three immature teratoma.
  • All but one patient received a combination of bleomycin, etoposide, and cisplatin (BEP) either as neoadjuvant (NACT, 3 cases) or as adjuvant therapy (28 cases).
  • In the present study, all 11 patients with dysgerminoma achieved sustained complete remission (CR), irrespective of the size of residual disease at the time of chemotherapy.
  • Four out of six cases (66.6%) with bulky nondysgerminomatous tumor achieved CR, which was sustained in three cases and one recurred.
  • This study indicates that there may be a role for aggressive cytoreductive surgery, either primary/interval or at the time of second-look laparotomy, in selected patients with nondysgerminomatous germ cell tumor of the ovary.
  • [MeSH-major] Germinoma / surgery. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Child. Child, Preschool. Cisplatin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Neoplasm Recurrence, Local. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11520369.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


37. Tangour-Bouaicha M, Bel Haj Salah M, Ben Brahim E, Ben Othmène M, Douggaz A, Sassi S, Chatti-Dey S: [Primary peritoneal yolk sac tumour. A case report]. Ann Pathol; 2010 Oct;30(5):378-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary peritoneal yolk sac tumour. A case report].
  • [Transliterated title] Tumeur vitelline péritonéale primitive. À propos d'une observation.
  • Yolk sac tumours are rare germinal neoplasms that often arise in ovary and testis.
  • We report a case of a 16-year-old girl who underwent laparotomy for an acute abdominal pain and circulatory dysfunction.
  • Microscopic examination of the pathologic specimen concluded to a yolk sac tumour.
  • Patient underwent intensive chemotherapy; she's free of disease 2 years after diagnosis.
  • Through this case, clinicopathologic features of this rare neoplasm will be discussed.
  • [MeSH-major] Endodermal Sinus Tumor / pathology. Peritoneal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Masson SAS.
  • (PMID = 21055525.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


38. Abe A, Furumoto H, Yoshida K, Nishimura M, Irahara M, Kudo E, Sano T: A case of ovarian endometrioid adenocarcinoma with a yolk sac tumor component. Int J Gynecol Cancer; 2008 Jan-Feb;18(1):168-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of ovarian endometrioid adenocarcinoma with a yolk sac tumor component.
  • Endometrioid adenocarcinoma of the ovary coexists very rarely with yolk sac tumor (YST).
  • This unusual mixed tumor is thought to be a rare variant of endometrioid ovarian carcinoma because of its aggressive behavior, lack of response to chemotherapy, and unfavorable prognosis.
  • We report a case of ovarian endometrioid adenocarcinoma with a YST component in a postmenopausal woman.
  • She has been clinically free of tumor for 20 months.
  • The occurrence of this unusual case suggests that even somatic carcinomas may acquire an extraembryonal germ cell differentiation.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endodermal Sinus Tumor / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Bridged Compounds / administration & dosage. Cisplatin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Immunoenzyme Techniques. Middle Aged. Platinum / administration & dosage. Taxoids / administration & dosage. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. PLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17466041.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bridged Compounds; 0 / Taxoids; 0 / alpha-Fetoproteins; 11056-06-7 / Bleomycin; 1605-68-1 / taxane; 49DFR088MY / Platinum; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


39. Ali L, Bambach BJ, Kozielski R, Wagner H, Lele S, Mhawech-Fauceglia P: Ovarian yolk sac tumor associated with major fibrosarcoma component in a 13-year-old girl. Int J Gynecol Pathol; 2010 May;29(3):252-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian yolk sac tumor associated with major fibrosarcoma component in a 13-year-old girl.
  • We are presenting a case of a 13-year-old girl with a chief complaint of lower abdominal pain.
  • A computed tomographic scan showed a 10-cm right ovarian mass.
  • The final diagnosis was a yolk sac tumor with a major (95%) fibrosarcoma component, based on morphology and further confirmed by an extensive panel of immunohistochemistry.
  • The patient completed 7 cycles of multiagent chemotherapy with cisplatin without major complications.
  • To our knowledge, our case is the first of its kind in the literature to document yolk sac tumor associated with fibrosarcoma in a teenage female.
  • [MeSH-major] Endodermal Sinus Tumor / pathology. Fibrosarcoma / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • Genetic Alliance. consumer health - Yolk sac tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20407325.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


40. Rebischung C, Pautier P, Morice P, Lhomme C, Duvillard P: Alpha-fetoprotein production by a malignant mixed Müllerian tumor of the ovary. Gynecol Oncol; 2000 Apr;77(1):203-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-fetoprotein production by a malignant mixed Müllerian tumor of the ovary.
  • Elevated levels of alpha-fetoprotein (AFP), a fetal serum protein, usually signal the development of hepatoma or germ cell tumors, including endodermal sinus tumors.
  • We report the case of a 52-year-old woman with an alpha-fetoprotein-producing malignant mixed Müllerian tumor (MMMT) of the ovary.
  • Serum AFP was 5348 ng/ml at diagnosis.
  • Immunohistochemistry confirmed that the carcinomatous component of this biphasic tumor was the seat of AFP production.
  • After three cycles of combination chemotherapy, the patient achieved a complete remission.
  • Serum AFP was strongly correlated with response to treatment.
  • This is the first report of AFP production by a MMMT of the ovary without a yolk sac component.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Mixed Tumor, Mullerian / metabolism. Ovarian Neoplasms / metabolism. alpha-Fetoproteins / biosynthesis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Immunohistochemistry. Middle Aged. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • (PMID = 10739713.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins
  •  go-up   go-down


41. Palenzuela G, Martin E, Meunier A, Beuzeboc P, Laurence V, Orbach D, Frappaz D: Comprehensive staging allows for excellent outcome in patients with localized malignant germ cell tumor of the ovary. Ann Surg; 2008 Nov;248(5):836-41
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comprehensive staging allows for excellent outcome in patients with localized malignant germ cell tumor of the ovary.
  • BACKGROUND: The management of malignant germ cell tumors of the ovary (OMGCT) requires multidisciplinary expertise.
  • We analyze the surgical and medical outcomes of a cohort of patients treated for OMGCT.
  • PATIENTS AND METHODS: Data concerning diagnosis, surgery, and medical decisions were reviewed for all patients seen for postoperative management of OMGCT at the Centre Léon Bérard in Lyon and the Institut Curie in Paris between 1985 and 2003.
  • Sixty patients aged 0.4 to 27.9 years (mean 12.8 years) at diagnosis were included.
  • Relapses occurred in 8 of 24 stage I tumors that were observed (0/8 stage Ia; 5/13 stage Ix (P = 0.044) and 3/3 stage Ic) versus 0/14 stage I treated by adjuvant chemotherapy (P = 0.0015).
  • The risk of relapse was significantly increased if patients underwent postsurgical observation ((HR) = 4.5 (95% CI, 1.5 to 13.3)), and when the tumor contained yolk sac tumor (HR = 7.3 (95% CI, 2.3 to 22.7)).
  • There was no significant prognostic value for age, stage, level of tumor markers at diagnosis, type of surgery, and type of chemotherapy.
  • Patients with stages Ix and Ic tumors may benefit from adjuvant chemotherapy.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / surgery. Ovarian Neoplasms / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Child. Dysgerminoma / diagnosis. Dysgerminoma / surgery. Endodermal Sinus Tumor / pathology. Endodermal Sinus Tumor / surgery. Fallopian Tubes / surgery. Female. Humans. Neoplasm Staging. Ovariectomy. Radiotherapy, Adjuvant. Retrospective Studies. Teratoma / diagnosis. Teratoma / pathology. Teratoma / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Malignant germ cell tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18948812.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


42. Ratnapala SR, Ratnapala SD: Pregnancy after excision of a yolk sac tumour of the ovary followed by chemotherapy. Ceylon Med J; 2004 Dec;49(4):134-5
MedlinePlus Health Information. consumer health - Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pregnancy after excision of a yolk sac tumour of the ovary followed by chemotherapy.
  • [MeSH-major] Dysgerminoma / diagnosis. Dysgerminoma / therapy. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / therapy. Pregnancy. Pregnancy Outcome. Pregnancy, High-Risk. Yolk Sac / pathology
  • [MeSH-minor] Adult. Cesarean Section. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Ovariectomy / methods. Risk Assessment






Advertisement